Dorff Tanya B, Tangen Cathy M, Crawford E David, Petrylak Daniel P, Higano Celestia S, Raghavan Derek, Quinn David I, Vogelzang Nicholas J, Thompson Ian M, Hussain Maha H A
University of Southern California, Los Angeles, CA.
Ther Adv Med Oncol. 2009;1(2):69-77. doi: 10.1177/1758834009343454.
The major goals of the SWOG-GU committee in the area of advanced prostate cancer are to improve the survival and quality of life of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.
SWOG泌尿生殖委员会在晚期前列腺癌领域的主要目标是提高晚期前列腺癌患者的生存率和生活质量。SWOG试验研究了联合雄激素阻断、间歇性雄激素剥夺以及在未经去势治疗的疾病中早期应用化疗的作用。此外，这些试验推动了目前多西他赛加泼尼松化疗标准的发展，正在进行的试验旨在改进这一标准。最后，已确定了替代终点，并且正在积极研究采用新技术的治疗反应或耐药性标志物。本综述重点介绍了SWOG近期晚期前列腺癌临床试验的结果，强调了这些数据的临床影响和未来应用。
